Aquila Diagnostic Systems Releases Independent Trial Results for Its AccutasVET Tapeworm Fecal Test

The study demonstrated that the diagnostic performance characteristics of the AccutasVET Tapeworm fecal test are clinically significant and exceed the diagnostic performance of current practices and currently available in-clinic tapeworm test kits.


Nov. 15, 2017 17:14 UTC

EDMONTON, Alberta--(BUSINESS WIRE)-- Aquila Diagnostic Systems (“Aquila”) is pleased to announce results of an independent laboratory trial for its point-of-care AccutasVET DNA Tapeworm fecal test based on Aquila’s patented molecular diagnostics hydrogel technology.

The independent study demonstrated that the diagnostic performance characteristics of the AccutasVET Tapeworm fecal test are clinically significant and exceed the diagnostic performance of current practices and currently available in-clinic tapeworm test kits.

The AccutasVET product is a disruptive animal health molecular diagnostic technology which is easy to use, and is highly sensitive and specific. AccutasVET can operate on any Aquila-certified industry-standard PCR instrument.

Aquila’s patented hydrogel technology can detect DNA and RNA from complex mediums such as fecal samples and is specifically suited for use in veterinary clinics and challenging remote locations such as barnyards, horse farms, and near-by water sources, with a sample-to-results time of less than 2 hours.

The independent study was run by Brent Wagner from July 10, 2017 to August 3, 2017 in the veterinary diagnostic laboratory of Dr. Emily Jenkins (Zoonotic Parasite Research Unit) at the University of Saskatchewan. This work supports Aquila’s December 2016 regulatory application to the US Department of Agriculture’s Center for Veterinary Diagnostics.

About Aquila Diagnostic Systems Inc.

Aquila Diagnostic Systems Inc.’s patented Accutas technology allows gold-standard molecular diagnostic (DNA/RNA) tests to be performed at a veterinary clinic or in the field using non-standard mediums such as fecal material with a sample-to-results time of 2 hours or less. Accutas molecular diagnostic tests may be performed on any Aquila-certified industry standard PCR instrument. Accutas eliminates waiting for results when samples are sent to regional laboratories and replaces inaccurate tests with gold-standard Accutas nucleic acid diagnostic tests. Accutas revolutionizes diagnostics for companion and food production animals.

For more information on Aquila please visit www.aquiladiagnostics.com

Contacts

Aquila
Mr. Brent James
CEO
brent@aquiladiagnostics.com

Source: Aquila Diagnostic Systems Inc.

MORE ON THIS TOPIC